The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.
April 14th 2024
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Olaparib Proves Versatile When Paired With AKT Inhibitor
April 22nd 2015The combination of olaparib with the novel AKT-targeting agent AZD5363 generated responses in a variety of tumor types among patients with and without BRCA1/2 mutations, demonstrating that a simultaneous attack on the two pathways is a safe and potentially versatile strategy.
Olaparib Plus BKM120 Combo Gains Traction in Breast and Ovarian Cancers
April 21st 2015A two-pronged strategy combining the PARP inhibitor olaparib and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with triple-negative breast cancer and for patients with high-grade serous ovarian cancer.
Dr. Matulonis on Toxicities With Olaparib for Patients With Ovarian Cancer
April 7th 2015Ursula A. Matulonis, MD, medical director, gynecologic oncology, Susan F. Smith Center for Women's Cancers, institute physician, Dana-Farber Cancer Institute, discusses managing toxicities associated with olaparib for patients with ovarian cancer.
Rucaparib Receives Breakthrough Designation for BRCA-Positive Advanced Ovarian Cancer
The FDA has granted a breakthrough therapy designation to rucaparib as a treatment for women with BRCA-mutated advanced ovarian cancer who have received at least two prior lines of platinum-based chemotherapy.
Fosbretabulin/Bevacizumab Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer
Fosbretabulin plus bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in patients with recurrent ovarian cancer.
Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer
Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.
New Ovarian Cancer Guidelines Include Surgery, Chemotherapy and Therapy Advancements
March 18th 2015Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of bevacizumab and olaparib, and intraperitoneal chemotherapy, have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines.
Analysis Shows Increased Ovarian Cancer Risk From Hormone Replacement Therapy
February 17th 2015The risk of developing the two most common types of ovarian cancer significantly increases when taking hormone replacement therapy to alleviate symptoms of menopause, according to a meta-analysis of epidemiological studies.
Dr. Wright on Measuring Progression and Recurrence in Ovarian Cancer
February 16th 2015Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer.
Dr. Donna McNamara on PARP Inhibitors for Ovarian Cancer Treatment
January 20th 2015Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, talks about the benefits of PARP inhibitors for women with BRCA1 or BRCA2-mutated, platinum-sensitive ovarian cancer.
HIPEC for Ovarian Cancer: An Exciting Locoregional Strategy
January 13th 2015Approximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.
BRCA Pioneer Offit Shares Insights on Evolving Testing Landscape
For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.
Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer
December 31st 2014Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.